ABSTRACT-We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incor porated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98% growth inhibition on Day 31 postinoculation and a survival advantage of a 339% increase in life span. After the implantation of the ADR-HAP bead (0.4 mg/bead/body) and the i.v. administration of an equal dose of free adriamycin, we determined the tissue distribution of ADR for up to 90 days. ADR-HAP bead implanted in the tumors released ADR over a 12-week period in the target area. The diffusion of the drug to other organs such as the heart and liver was very low compared with the tumors. The area under the ADR concentration-time curve (AUC) of the tumors was 181.6 ug • day/g and 5.22 pg • day/g after the implantation of the ADR-HAP bead and the i.v. administration of free ADR, respectively. The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8. The targeting indices of 0.16 and 0.17 for the heart and liver, respectively, indicate that the implantation of the ADR-HAP bead reduced delivery of ADR to these organs. These results demonstrate that this method of administration may be useful in delivering adjuvant chemotherapy in order to prevent local recurrence in the site of the bony defect after the surgical removal of bone tumors.
In general, the therapy of malignant bone tumors con sists of the combination of en bloc resection with chemotherapy and/or radiation (1) . However, bony curet tage has its limitations because of the possible persistence of tumor cells. Moreover, there were still unsolved problems with regards to the management of the bony defect and the reduction of the possible toxic side-effects of the antineoplastic agents employed.
Although adriamycin (ADR) is one of the anticancer drugs most widely used against malignant bone tumors (2), its systemic use is often limited due to its cardiotoxic and other undesirable side effects (3) . An appropriate drug delivery system that slowly releases an anticancer drug exclusively into the tumor would be promising for both enhancing the therapeutic efficiency for local control of the tumors and for reducing the risk of toxic side effects.
Hydroxyapatite (HAP) is the major mineral compo nent of bone and teeth. Synthetic HAP shows chemical and physical properties similar to those of bone. It has been reported that porous HAP enjoys an excellent biocompatibility with bony tissue, and it can be partly ab sorbed when used in orthopedics as a replacement sub stance following local excision with the bony curettage of bone tumors or osteoarthrosis (4) . No surgical procedure is required for removal when anticancer drugs are present in a HAP bead. We have reported in a preliminary study that the ADR-loaded HAP bead offers a potentially effec tive method of anticancer drug delivery (5) . In the present paper, we describe the dose-dependency of the antitumor effects of an ADR-loaded HAP bead and the tissue distri bution of ADR from the HAP bead compared with i.v. administration in rats bearing Swarm rat chondrosar coma.
MATERIALS AND METHODS

Chemicals
ADR injection (Adriacin®, 10 mg/vial) and ADR-HC1 were supplied from Kyowa Hakko Kogyo Co., Ltd., Tokyo. The porous HAP beads were a gift from NGK Spark Plug Co., Ltd., Nagoya. The physical data of the beads (XVC-56) were as follows: sintering temperature, 11001C; diameter, 8.48 mm; weight of one bead, 531 ±0.7 mg; bulk density, 1.66; true density of the material, 2.97; and Ca/P, 1.68. Distilled water and acetonitrile were of high performance liquid chro matography (HPLC) quality. All other chemicals were of reagent grade.
Animals
Four-week-old male Sprague-Dawley (SD) rats weigh ing 85-92g
were obtained from Japan SLC, Ltd., Hamamatsu.
Tumor
The Swarm rat chondrosarcoma was isolated from a tumor that originally arose spontaneously in a female SD rat (6); histologically, it shared certain features with a well-differentiated (grade I) human chondrosarcoma such as moderate cellularity and mild nuclear hyperchromasia (7) . In this study, the Swarm rat chondrosarcoma was maintained by subcutaneous transplantation into SD rats in our laboratory (5) . Tumor cell suspensions (107 cells/ml) in 0.9010 NaC1 solution were prepared by minc ing the surgically obtained tumor through a stainless steel sieve (pore size, 1-mm2). The tumor pieces were digested for about 90 min sequentially with 0.5010 trypsin and 0.5% collagenase. The concentration of cells released was determined by a counter for bio-cells (Elzone® Model 80; Elmhurst, IL, USA). Tumor cell suspensions (1 ml) were inoculated s.c. into the armpit sites of SD rats on Day 0. All rats used in a single experiment (6 rats in a group) were inoculated on the same day with cells from the same tumor. When the tumor cell suspension (107 cells) was in oculated s.c. into four-week-old SD rats, the tumor size reached about ^-1.0 cm3 by 1 week postinoculation and -196 cm3 by 4 weeks .
Preparation of ADR-HAP beads HAP beads were washed with freshly distilled water once a day for a week to remove unknown water-soluble substances and ions and then dried in a desiccator with a vacuum pump and sterilized by autoclaving. The drug amount loaded in the bead was estimated from the mean full displacement of the pore spaces with water (0.140±0.001 ml, n=10). Empty HAP beads were placed in an ADR aqueous solution (2.86-42.86 mg/ml) at 51C under atmospheric pressure and allowed to remain for 1 hr. HAP beads containing drug solution were lightly wiped with a filter paper and lyophilized in a freeze drying apparatus (8) .
Evaluation of antitumor effects Free ADR (0.4 mg/body) in saline was injected i.v. on Day 6 postinoculation.
One ADR-HAP bead (0.4-6.0 mg/bead/body) was implanted into the central portion of the tumor. Drug-free HAP beads were implanted in the same manner to investigate any effects of the HAP beads themselves. Tumor growth rates were determined by meas uring the tumor volumes with a caliper every 3 to 4 days postinoculation. The tumor volume (V) was calculated by the formula 1/2ab2, where a is the long diameter and b is the short diameter. The tumor volume was expressed as the relative tumor volume (RV), RV = V/Vo, where V is the tumor volume on the day of measurement, and Vo is the initial volume on day 6 (when the treatment was start ed) (9) . The antitumor effect was evaluated by comparing the mean survival time of the treated group (T) with that of the control group (C) and expressing it as "increase in life span" (ILS) or "tumor growth inhibition" on Day 31 postinoculation.
ILS=(T/C-1) x 100
Tissue distribution studies Rats bearing Swarm rat chondrosarcoma were given either a single i.v. administration of free ADR (0.4 mg/body) or an implantation of ADR-HAP bead (0.4 mg/bead/body) on Day 6. Blood samples (0.5 ml) were taken from the femoral vein at 5, 10, 20, 30, 60, 180 and 360 min. The blood was collected in heparinized tubes under ether anesthesia, and centrifuged immediately at 3,000 rpm. The plasma supernatants were collected and frozen at 80V until determination. The excised tumor, heart and liver were rapidly washed with sterilized saline and cut into small pieces in 2 ml of 10 mM phosphate buffered saline (pH 7.0). These were homogenized with a Polytron homogenizer at 41C to make a 5 -10010 homog enate. The homogenate was centrifuged at 12,000 rpm for 5 min. ADR contents in the supernatant was deter mined by HPLC (10).
Statistical analyses
Statistical differences between the control and drug-free HAP treatment values within the groups were determined by Student's t-test, and the differences between the groups were studied by analysis of variance (Scheffe's F-test). A P value of <0.05 was considered significant. 
RESULTS
Chemotherapeutic effects against Swarm rat chondrosar coma The antitumor effects of local and systemic ADR on this tumor system are shown in Table 1 and Fig. 1 . No effect on tumor growth was observed in rats implanted drug-free HAP beads compared with the non-treated con trol. The ADR-HAP beads showed good therapeutic effects in a dose-dependent fashion. When compared with an equal dose (0.4 mg/body) given by systemic administra tion, the ADR-HAP bead showed more tumor inhibitory effects on Swarm rat chondrosarcoma. The ADR-HAP beads (0.4 mg/bead) showed chemotherapeutic effects of 69a%o ILS and a tumor inhibition rate of 33%, whereas sin gle i.v. injection showed lower effects of 13% ILS and a tumor inhibition rate of 11 %. At the tested doses of ADR (4.0 to 6.0 mg/bead), more than 90% tumor growth inhi bition was obtained. The dose of 6.0 mg/bead showed the greatest efficacy compared with the other groups: No toxic death was caused, and there was 98% growth inhibi tion on Day 31, and a survival advantage of a 339% ILS. 
ADR levels in serum
The maximum serum levels of ADR were observed at 5 min after the injection of free ADR, and a rapid clearance of the drug from the circulation was shown (Fig. 2) . After the implantation of the ADR-HAP bead, the drug was de tected only at very low levels when compared with those associated with i.v. administration.
ADR levels in tumor
The maximum level of free ADR after i.v. injection of free ADR was 6.7 pg/g at 6 hr, and then ADR levels grad ually decreased (Fig. 3) . Twelve hours after the implanta tion of the ADR-HAP bead, however, ADR levels in the tumors were observed to be significantly higher than those following the i.v. administration of free ADR (Fig. 3) , and ADR was detectable for up to 90 days. The maximum ADR levels in the tumors after implantation of the ADR HAP bead was 16.2 pg/g at 6 days, 2.4 times higher than the maximum concentration after the i.v. administration of free ADR. The area under the ADR concentration time curve (AUC) was 181.61Cg • day/g after the implanta tion of the ADR-HAP bead and 5.22 pg • day/g after the i.v. injection of free ADR. The targeting index was 34.8 for the implantation of the ADR-HAP bead (Table 2) . In short, when compared with the i.v. administration, the ADR-HAP bead administration enhanced the delivery of the drug to the tumors.
AUC values of ADR and targeting indices in the heart and liver
Compared with the AUC values after the i.v. adminis tration of free ADR, those in the heart and liver were low after the implantation of the ADR-HAP bead (Table 2) . In the heart, the AUC values was 1.81 pg • day/g after the implantation of the ADR-HAP bead and 11.2 ug • day/g after the i.v. administration of free ADR. The targeting index was 0.16. In the liver, the AUC values were 1.53 jig • day/g after the implantation of the ADR-HAP bead and 9.21 pg • day/g after the i.v. administration of free ADR. The targeting index was 0.17. AUC values for the 12-24 days after implantation of the ADR-HAP bead were 21.78 pg • day/g in the tumor, 0.14 pg • day/g in the liver and 0.15 pg • day/g in the heart. Table 2 .
AUC values of ADR and targeting index DISCUSSION ADR is an anticancer drug with broad activity against a number of human neoplasms (2) . It is difficult to control local recurrence and pulmonary metastases by i.v. injec tion after bone tumor surgery. In most cases, hydrophilic anticancer drugs, such as anthracyclinces and mytomycin C used clinically, appear to be rapidly absorbed from the interstitial space through the capillaries, resulting in a low drug concentration at the operated site (11) . This was confirmed in the present investigation, because a rapid clearance from the plasma was observed following an i.v. administration of ADR (Fig. 2) . It is believed that in com parison with intravenous administration, intra-arterial infusion of anticancer drugs achieves high local levels of drugs in tumors and reduces systemic toxicity (12, 13) . This local delivery method may be effective in decreasing the size of the bone tumors, but it cannot be used postoperatively. Therefore, it may be useful to fill up the bony defect after excision with a bone graft incorporated with an active anticancer drug; such an implant would be expected to release active agents for a specific duration. Guan et al. (14) experimented with the incorporation of antineoplastics into bone cement powder for implanta tion in rat tumors and reported that the antineoplastic effect was higher than for i.v. administration.
Blocks, plates or beads are preferable to powder for maintaining bone structure and skeletal support to the body in cases where widespread bone defects exist after surgery for bone tumor. The beads used in our experiment were iden tical in size and composition and composed of a bone graft used clinically. The number of beads used in each case was sufficient to fill the volume of each bone defect. Therefore, to avoid side effects and achieve chemo therapy, it is important to know the antitumor ef fects and distribution of the drug in order to predict the amounts of antineoplastics incorporated as the number of beads increases. In our preliminary study, we demon strated that an ADR-loaded HAP bead is effective when implanted in the Swarm rat chodrosarcoma (5). To ex plore the usefulness of this method targeting regional chemotherapy on the bone tumors, we investigated in this study the anticancer effects and ADR delivery to various organs in a rat model after the implantation of the ADR HAP bead, in comparison with i.v. administration. Evi dence from the present experiments indicate that the drug effects for chemotherapy were well-correlated with the dose of drug incorporated in the HAP bead ( Table 1) . The dose of 6.0 mg/bead showed the highest efficacy: It showed a 98010 growth inhibition on Day 31 and a survival advantage of a 339% increase in life span without toxic death. ADR delivery was expressed as the area under the tissue ADR concentration-time curve (Table 2 ). The AUC in the tumor after the implantation of the ADR-HAP bead was significantly higher than that after the i.v. ad ministration of free ADR. In addition, after the implanta tion of the ADR-HAP bead, the AUC in the tumors was significantly higher than that in other tissues. The target ing index for the tumors was 34.8 after the implantation of the ADR-HAP bead. The targeting indices for the heart and the liver after the implantation of the ADR HAP bead were very low, indicating that unfavorable ADR delivery to these organs was reduced. ADR was hardly detected in the plasma, except for a very small amount (0.05 pg/ml) at 20 min after implantation of the ADR-HAP bead (Fig. 2) . This ADR delivery system produced a high concentration and a prolonged retention of the drug at the site of the tumor, but a low concentra tion in the systemic circulation and other organs. These findings indicated that the clinical trials of this system will allow us to control more effectively bone tumors after sur gery.
